Plain-English translation of NCT07678112 on ClinicalTrials.gov ↗ · Source last updated ·
This study doesn't follow the usual testing phases — it may be an observational study or a different type of research.
This trial is testing a new decision-support tool called OPTIBIO that uses blood tests and clinical information to predict whether it's safe to reduce or stop anti-TNF biological therapy (such as infliximab, adalimumab, etanercept, golimumab, or certolizumab) in people with rheumatoid arthritis who are in remission. The study compares treatment decisions made with this medication guidance tool versus standard doctor judgment alone, to see if the tool helps prevent disease flares while safely reducing unnecessary treatment.
Many arthritis patients who achieve remission can potentially reduce their medications safely, but doctors currently make these decisions mostly by guesswork, which can lead to either dangerous flares or unnecessary ongoing treatment. This tool was developed to give doctors a personalized, scientific way to predict which patients can safely have their medication adjusted and which should continue at full doses.
You likely qualify if…
You likely don't qualify if…
You will be randomly assigned to either have your treatment decisions guided by the new blood-based tool or by standard doctor judgment. You will have blood drawn to provide the information the tool uses, and your doctor will then decide whether to adjust your medication based on that information (or on standard practice, depending on your group). The study tracks whether you remain in remission or experience a disease flare over the follow-up period.
AI-generated summary from trial data · Jul 1, 2026 · Not medical advice
Spain